File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Fetal and neonatal outcome of exposure to anticoagulants during pregnancy

TitleFetal and neonatal outcome of exposure to anticoagulants during pregnancy
Authors
Keywordsanticoagulant
embryopathy
heparin
warfarin
Issue Date1993
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at
Citation
American Journal Of Medical Genetics, 1993, v. 45 n. 1, p. 17-21 How to Cite?
AbstractWe studied fetal and neonatal outcome of women maintained on anticoagulants (warfarin and/or heparin) during pregnancy. Among 22 Chinese families, 13 mothers (59%) had a history of recurrent abortion or stillbirth while being maintained on warfarin treatment. Twenty-nine liveborn children (17 boys, 12 girls), ages 0.6-11.3 years at follow-up, were analysed for evidence of embryopathy. These were subdivided into 2 groups. Group 1 consisted of 18 children (12 boys, 6 girls) whose mothers were only given warfarin during pregnancy. Five were small for gestational age, and 12 had features of warfarin embryopathy such as nasal hypoplasia. One had subependymal intraventricular hemorrhage shown on neonatal ultrasonography. Group 2 consisted of 11 children (5 boys, 6 girls) whose mothers were maintained on warfarin and heparin during pregnancy. Three were premature deliveries, and 4 had nasal hypoplasia. One had cleft lip, cleft palate, cataract, microphthalmia, intraventricular hemorrhage, and hydrocephalus. We found that despite the high risk of fetal wastage, there was a relative lower risk of major complications, except for some minor cosmetic defects such as nasal hypoplasia. This might lead to readjustment of advice concerning contraception given to pregnant women who were maintained on anticoagulant therapy.
Persistent Identifierhttp://hdl.handle.net/10722/143598
ISSN
2003 Impact Factor: -999.999
2009 SCImago Journal Rankings: 1.100
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorWong, Ven_HK
dc.contributor.authorCheng, CHen_HK
dc.contributor.authorChan, KCen_HK
dc.date.accessioned2011-12-12T03:52:12Z-
dc.date.available2011-12-12T03:52:12Z-
dc.date.issued1993en_HK
dc.identifier.citationAmerican Journal Of Medical Genetics, 1993, v. 45 n. 1, p. 17-21en_HK
dc.identifier.issn0148-7299en_HK
dc.identifier.urihttp://hdl.handle.net/10722/143598-
dc.description.abstractWe studied fetal and neonatal outcome of women maintained on anticoagulants (warfarin and/or heparin) during pregnancy. Among 22 Chinese families, 13 mothers (59%) had a history of recurrent abortion or stillbirth while being maintained on warfarin treatment. Twenty-nine liveborn children (17 boys, 12 girls), ages 0.6-11.3 years at follow-up, were analysed for evidence of embryopathy. These were subdivided into 2 groups. Group 1 consisted of 18 children (12 boys, 6 girls) whose mothers were only given warfarin during pregnancy. Five were small for gestational age, and 12 had features of warfarin embryopathy such as nasal hypoplasia. One had subependymal intraventricular hemorrhage shown on neonatal ultrasonography. Group 2 consisted of 11 children (5 boys, 6 girls) whose mothers were maintained on warfarin and heparin during pregnancy. Three were premature deliveries, and 4 had nasal hypoplasia. One had cleft lip, cleft palate, cataract, microphthalmia, intraventricular hemorrhage, and hydrocephalus. We found that despite the high risk of fetal wastage, there was a relative lower risk of major complications, except for some minor cosmetic defects such as nasal hypoplasia. This might lead to readjustment of advice concerning contraception given to pregnant women who were maintained on anticoagulant therapy.en_HK
dc.languageengen_US
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located aten_US
dc.relation.ispartofAmerican Journal of Medical Geneticsen_HK
dc.subjectanticoagulanten_HK
dc.subjectembryopathyen_HK
dc.subjectheparinen_HK
dc.subjectwarfarinen_HK
dc.subject.meshAbortion, Habitual/chemically induceden_US
dc.subject.meshChilden_US
dc.subject.meshChild, Preschoolen_US
dc.subject.meshFemaleen_US
dc.subject.meshFetal Diseases/*chemically induceden_US
dc.subject.meshFollow-Up Studiesen_US
dc.subject.meshHeparin/*adverse effects/therapeutic useen_US
dc.subject.meshHumansen_US
dc.subject.meshInfanten_US
dc.subject.meshInfant, Newbornen_US
dc.subject.meshInfant, Newborn, Diseases/*chemically induceden_US
dc.subject.meshMaleen_US
dc.subject.meshPregnancyen_US
dc.subject.meshPregnancy Complications, Cardiovascular/drug therapyen_US
dc.subject.mesh*Prenatal Exposure Delayed Effectsen_US
dc.subject.meshWarfarin/*adverse effects/therapeutic useen_US
dc.titleFetal and neonatal outcome of exposure to anticoagulants during pregnancyen_HK
dc.typeArticleen_HK
dc.identifier.emailWong, V:vcnwong@hku.hken_HK
dc.identifier.authorityWong, V=rp00334en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1002/ajmg.1320450107en_HK
dc.identifier.pmid8418652-
dc.identifier.scopuseid_2-s2.0-0027471139en_HK
dc.identifier.volume45en_HK
dc.identifier.issue1en_HK
dc.identifier.spage17en_HK
dc.identifier.epage21en_HK
dc.identifier.isiWOS:A1993KR91500005-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridWong, V=7202525632en_HK
dc.identifier.scopusauthoridCheng, CH=37053188100en_HK
dc.identifier.scopusauthoridChan, KC=35274389700en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats